MISTMilestone Pharmaceuticals Inc
MIST
Milestone Pharmaceuticals Inc6,219
Mkt Cap
$196.74MVolume
2.9M52W High
$2.7552W Low
$0.6254PE Ratio
-2.78MIST Fundamentals
Price
$2.40Prev Close
$2.31Open
$2.3550D MA
$1.99Beta
1.25Avg. Volume
1.48MEPS (Annual)
-$0.6674P/B
9.97Rev/Employee
$0.00What is HC Wainwright's Estimate for MIST FY2025 Earnings?
Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Research analysts at HC Wainwright raised their FY2025 earnings estimates for shares of Milestone Pharmaceuticals in a note issued to...
MarketBeat·5d ago
Milestone Pharmaceuticals (NASDAQ:MIST) Announces Earnings Results, Beats Expectations By $0.05 EPS
Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus...
MarketBeat·9d ago
Simplify Asset Management Inc. Purchases 140,000 Shares of Milestone Pharmaceuticals Inc. $MIST
Simplify Asset Management Inc. lifted its position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 16.5% in the 2nd quarter, according to its most recent Form 13F filing...
MarketBeat·10d ago
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
Zacks·6mo ago
TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty
Investing.com -- TD Securities downgraded Milestone Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for its lead drug, etripamil, following a Complete Response Letter from the U.S. Food and Drug Administration.The FDA issued a Complete Response Letter for MIST’s etripamil New Drug Application for paroxysmal supraventricular tachycardia (pSVT), citing chemistry, manufacturing, and controls issues. While no safety or efficacy concerns were raised, the agency requested additional data on nitrosamine impurities based on new draft guidance published in September 2024, months after MIST had resubmitted its New Drug Application . The FDA also flagged the need for an inspection at a third-party facility performing release testing, which changed ownership during the New Drug Application review.
investing.com·8mo ago
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive
The FDA said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices.
Milestone Pharmaceuticals Upgraded to Buy: Here's What You Should Know
Milestone Pharmaceuticals (NASDAQ: MIST) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings...
Benzinga·2y ago
Milestone Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
MONTREAL and CHARLOTTE, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will deliver a company...
Globe Newswire·2y ago
Milestone Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of...
Globe Newswire·2y ago
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...
Globe Newswire·2y ago